Education
About Us
Working with TipRanks
Follow Us
EKSO BIONICS (EKSO)
NASDAQ:EKSO
EKSO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.34 - $1.53
Previous CloseN/A
Volume1.71M
Average Volume (3M)242.45K
Market Cap
$12.14M
Enterprise Value$21.61M
Total Cash (Recent Filing)$6.49M
Total Debt (Recent Filing)$5.98M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Apr 24, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding24,824,762
10 Day Avg. Volume230,234
30 Day Avg. Volume242,449
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.69
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.27
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$5.00Price Target Upside1011.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
EKSO BIONICS News
PremiumCompany Announcements
Ekso Bionics’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Ekso Bionics Reports Record Q4 Revenue and Strategic Partnership
---
Bulls Say, Bears Say
Bulls Say
Medicare ReimbursementEkso has engaged PRIA Healthcare to aid in building a repeatable process for Medicare reimbursement, expected to minimize headaches.
Strategic PartnershipsStrategic partnerships have been formed to broaden access to Ekso Indego Personal and navigate the reimbursement process, potentially expanding the market and driving long-term value for Ekso.
Bears Say
Cash Runway ConcernsThe company’s present forecasts suggest less than 12 months of cash runway, indicating a likely need to tap the equity markets.
Revenue PerformanceEkso Bionics reported revenues of $4.1M, lower than the consensus estimate of $5.5M, and a net loss of $0.10 per share.
---
Ownership Overview
5.59% Insiders
2.99% Mutual Funds
11.12% Other Institutional Investors
77.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
EKSO FAQ
What was EKSO BIONICS’s price range in the past 12 months?
EKSO BIONICS lowest stock price was $0.34 and its highest was $1.53 in the past 12 months.
What is EKSO BIONICS’s market cap?
EKSO BIONICS’s market cap is $12.14M.
When is EKSO BIONICS’s upcoming earnings report date?
EKSO BIONICS’s upcoming earnings report date is Apr 24, 2025 which is in 29 days.
How were EKSO BIONICS’s earnings last quarter?
EKSO BIONICS released its earnings results on Mar 03, 2025. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.06.
Is EKSO BIONICS overvalued?
According to Wall Street analysts EKSO BIONICS’s price is currently Undervalued.
Does EKSO BIONICS pay dividends?
EKSO BIONICS does not currently pay dividends.
What is EKSO BIONICS’s EPS estimate?
EKSO BIONICS’s EPS estimate is -0.11.
How many shares outstanding does EKSO BIONICS have?
EKSO BIONICS has 24,824,762 shares outstanding.
What happened to EKSO BIONICS’s price movement after its last earnings report?
EKSO BIONICS reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of EKSO BIONICS?
Currently, no hedge funds are holding shares in EKSO
---
Company Description
EKSO BIONICS
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
---
EKSO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive and negative trends. While there were record-breaking quarterly revenues, improved margins, and strategic partnerships, there were also challenges such as a decline in full-year revenue and increased net loss for the quarter. The company's strategic efforts to enhance market access and reimbursement processes indicate optimism for future growth.Read More>---
EKSO Stock 12 Month Forecast
Average Price Target
$5.00
▲(1011.11% Upside)
Technical Analysis
Best Analysts Covering EKSO
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-35.17%
reiterated a buy rating 24 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -35.17% per trade.
---